Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients

Fig. 2

Granulocytic MDSC (LIN−CD11b+CD15+) in the peripheral blood of HNSCC patients decreased after cetuximab treatment. Levels of granulocytic MDSC (LIN−CD11b+CD15+) in the peripheral blood of healthy donors versus HNSCC patients and patients pre- and post-cetuximab treatment were analyzed by flow cytometry. a Representative figures showing frequency of CD15+ cells in LIN−CD11b+ mononuclear cells in peripheral blood from healthy donors and HNSCC patients. b Representative figures showing percentage of CD15+ cells in circulating LIN−CD11b+ cells in HNSCC patients before and after cetuximab treatment. c Summary data of frequency of LIN−CD11b+CD15+ cells in live PBMC pre- and post-cetuximab treatment in the total 24 HNSCC patients (left panel, **p < 0.01) and in responders (n = 8, **p < 0.01) and non-responders (n = 16) of UPCI 08–013 trial (right panel). Statistical significance was determined by Wilcoxon matched-pairs signed rank tests. **p < 0.01. p > 0.05 was considered to be not significant (n.s.)

Back to article page